PATENT CLAIM ANALYSIS

Application Number: 15746398
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["435", "325000"]

Abstract:
Factors for extending the ability of isolated pluripotent stem cells to generate extraembryonic lineages in vivo, following in vitro culture, herein, chemical extenders of pluripotency (CEP). Methods of extending the ability of a pluripotent cell to generate embryonic and extraembryonic lineages. The cell to be reprogrammed is contacted with effective amounts of the CEPs for a sufficient period of time to reprogram the cell into a chemically induced extended pluripotent cell (ciEPSC). ciEPSC are identified as an extended pluripotent cell based on properties including: (i) morphologically and (ii) functionally for example, based on their ability contribute to both TE and ICM, in vivo. The ciEPSCs can be cultured or induced to differentiate into cells of a desired type, and used in a number of applications, including but not limited to cell therapy and tissue engineering.

Claim (Index 1):
A cell culture media composition for extending cell potency of isolated pluripotent cells, the composition comprising chemical extenders of pluripotency (CEP) from each of the following groups\n (1) a cytokine, (2) a glycogen synthase kinase (GSK) inhibitor, (3) a G protein coupled receptor (GPCR) inhibitor (4) a Poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, and (5) optionally, Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor, in amounts effective to induce reprogramming of an untreated cell, into an extended pluripotent cell, and optionally wherein (a) the cytokine is selected from the group consisting of human inhibitory fact (LIF, \u201cL\u201d), interleukin (IL)-6, IL-11, IL-27, IL-31, leukemia inhibitory factor, oncostatin M, cardiotrophin-1, neuropoietin and cardiotrophin-like cytokine factor 1; (b) the GSK inhibitor is a GSK3 inhibitor, and more preferably the GSK inhibitor is selected from the group consisting of CHIR99021 (\u201cC\u201d) [6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile]; BIO-acetoxime; GSK 3I inhibitor XV; SB-216763; CHIR 99021 trihydrochloride; GSK-3 Inhibitor IX [((2Z, 3E)-6\u2032-bromo-3-(hydroxyimino)-[2,3\u2032-biindolinylidene]-2\u2032-one]; GSK 3 IX [6-Bromoindirubin-3\u2032-oxime]; GSK-3\u03b2 Inhibitor XII [3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol]; GSK-3 Inhibitor XVI [6-(2-(4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino)ethyl-amino)-nicotinonitrile]; SB-415286 [3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione]; and Bio [(2\u2032Z,3\u2032E)-6-bromoindirubin-3\u2032-oxime]; (c) the GPCR inhibitor is an acetylcholine receptor antagonist, and more preferably the GPCR inhibitor is DiM ((S)-(+)-Dimethindene maleate) (\u201cD\u201d); and/or (d) the PARP1 inhibitor is selected from the group consisting of MiH (Minocycline hydrochloride) (\u201cM), BSI-201 (4-iodo-3-nitrobenzamide), NAM (Nicotinamide), PJ34 (N-(6-Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide; PARP Inhibitor XIV; 4-[(1-Methyl-1H-pyrrol-2-yl)methylene]-1,3(2H,4H)-isoquinolinedione; Veliparib; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide dihydrochloride; Olaparidb (1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine); 6-amino-1H-benz[de]isoquinoline-1; and INH2BP (5-Iodo-6-amino-1,2-benzopyrone).

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.81395
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14904195', '09436164', '12108852', '14735841', '12164795']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5608331527528769
- 35 USC 102 Novelty (BERT): 0.5180905882590138
- Combined Prediction Score: 0.5565588963034906
- Mean Citation Score: 321.480656
- Max Citation Score: 338.71844
- Similarity Product: 286.2281147898054

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test